Table 35All pooled results for on-study mortality

VariableDarbepoetin vs. EpoetinEpoetin vs. ControlDarbepoetin vs. ControlEpoetin or Darbepoetin vs. Control
Number of trials231637
Patients analyzed1,5678,6182,64811,266
Pooled hazard ratio0.901.19a,b1.05c1.17d,e,f
(95% confidence interval)(0.67 to 1.20)(1.05 to 1.36)(0.80 to 1.38)(1.04 to 1.31)
I272%3%0%0%
a

Including the trial enrolling pediatric patients left estimate and CI unchanged.

b

Estimate in Bayesian random effects model 1.16 (95% CrI: 1.00 to 1.32).

c

Estimate in Bayesian random effects model 1.10 (95% CrI: 0.76 to 1.58).

d

Estimate in Bayesian random effects model 1.15 (95% CrI: 1.02 to 1.31).

e

Including the trial enrolling pediatric patients left estimate and CI unchanged.

f

Excluding the 2 radiotherapy only trials34,81 1.16 (95% CI: 1.03 to 1.31), or the 3 trials classified here as radiotherapy or predominantly radiotherapy34,81,83 1.16 (95% CI: 1.03 to 1.30).

From: Results

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.